Travere Therapeutics, Inc.
TVTX
$14.50
$1.017.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 60.55% | 57.08% | 47.42% | 69.52% | 32.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.55% | 57.08% | 47.42% | 69.52% | 32.69% |
| Cost of Revenue | -12.17% | -10.42% | -5.64% | 4.14% | 10.65% |
| Gross Profit | 107.14% | 82.33% | 56.00% | 37.73% | 9.07% |
| SG&A Expenses | -0.54% | -0.32% | 6.87% | 21.75% | 34.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.24% | 7.49% | 13.84% | 27.01% | 21.60% |
| Operating Income | 14.69% | 9.38% | -2.92% | -16.17% | -17.80% |
| Income Before Tax | 14.78% | 6.55% | -4.14% | -18.10% | -13.58% |
| Income Tax Expenses | -46.19% | 19.27% | 1.42% | -0.88% | -28.75% |
| Earnings from Continuing Operations | 14.80% | 6.54% | -4.14% | -18.08% | -13.54% |
| Earnings from Discontinued Operations | -100.35% | -100.87% | 290.98% | 472.74% | 674.21% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -188.64% | -303.74% | 52.54% | 44.22% | 60.00% |
| EBIT | 14.69% | 9.38% | -2.92% | -16.17% | -17.80% |
| EBITDA | 17.85% | 11.97% | -0.62% | -13.93% | -16.74% |
| EPS Basic | -156.92% | -215.81% | 58.36% | 52.74% | 63.45% |
| Normalized Basic EPS | 17.74% | 17.11% | 10.65% | 4.96% | 2.76% |
| EPS Diluted | -156.92% | -215.81% | 58.36% | 52.74% | 63.45% |
| Normalized Diluted EPS | 17.74% | 17.11% | 10.65% | 4.96% | 2.76% |
| Average Basic Shares Outstanding | 6.25% | 8.50% | 12.85% | 17.75% | 16.56% |
| Average Diluted Shares Outstanding | 6.25% | 8.50% | 12.85% | 17.75% | 16.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
